InvestorsHub Logo
Followers 98
Posts 11272
Boards Moderated 7
Alias Born 06/06/2017

Re: None

Monday, 01/13/2020 8:07:48 AM

Monday, January 13, 2020 8:07:48 AM

Post# of 580
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
Recent CFRX News